Steve Seedhouse Analyst PerformanceEquity Research- Biotechnology at Cantor FitzgeraldSteve Seedhouse is a stock analyst at Cantor Fitzgerald in the healthcare sector, covering 17 publicly traded companies. Over the past year, Steve Seedhouse has issued 39 stock ratings, including strong buy, buy, and hold recommendations. While full access to Steve Seedhouse's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Steve Seedhouse's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings43 Last 1 YearsBuy Recommendations90.70% 39 Buy RatingsCompanies Covered17 Unique Companies Ratings Distribution43RatingsDistribution of strong buy, buy, hold, and sell ratings by Steve Seedhouse.RatingPercentageCount Strong Buy4.7%2 ratings Buy86.0%37 ratings Hold9.3%4 ratings Sell0.0%0 ratingsOut of 43 total stock ratings issued by Steve Seedhouse at Cantor Fitzgerald, the majority (86.0%) have been Buy recommendations, followed by 9.3% Hold and 4.7% Strong Buy.Best & Worst CallsBest Call000.0%HROWJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%TVRDJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ17 companiesSteve Seedhouse, an analyst at Cantor Fitzgerald, currently covers 17 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare17 companies100.0%Steve Seedhouse of Cantor Fitzgerald specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY12 companies70.6%PHARMACEUTICALS5 companies29.4% Steve Seedhouse's Ratings History at Cantor Fitzgerald Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsIFRXInflaRx8/7/2026Boost Price Target$1.72$6.00Overweight$0.0000.00% ROIINVAInnoviva8/7/2026Lower Price Target$21.11$34.00Overweight$0.0000.00% ROIXNCRXencor8/6/2026Boost Price Target$19.84$44.00Overweight$0.0000.00% ROIABCLAbCellera Biologics8/6/2026Boost Price Target$5.92$12.00Overweight$0.0000.00% ROIEYPTEyepoint Pharmaceuticals8/6/2026Boost Price Target$12.25$55.00Overweight$0.0000.00% ROIEYPTEyepoint Pharmaceuticals7/8/2026Initiated Coverage$14.02$47.00Overweight$0.0000.00% ROIALGSAligos Therapeutics5/29/2026Reiterated Rating$5.79Overweight$0.0000.00% ROIALGSAligos Therapeutics5/21/2026Initiated Coverage$5.60$20.00Overweight$0.0000.00% ROIALGSAligos Therapeutics5/21/2026Initiated Coverage$5.71$20.00Overweight$0.0000.00% ROIAPLSApellis Pharmaceuticals5/15/2026Reiterated Rating$41.03Neutral$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. HROWHarrow5/13/2026Lower Price Target$28.93$88.00Overweight$0.0000.00% ROIIFRXInflaRx5/11/2026Boost Price Target$2.69$4.00Overweight$0.0000.00% ROIABCLAbCellera Biologics5/5/2026Initiated Coverage$4.59$7.00Overweight$0.0000.00% ROIVKTXViking Therapeutics4/30/2026Lower Price Target$31.33$100.00Overweight$0.0000.00% ROIAPLSApellis Pharmaceuticals3/31/2026Downgrade$40.39Hold$0.0000.00% ROIIRDOpus Genetics3/30/2026Initiated Coverage$4.35$15.00Overweight$0.0000.00% ROISRZNSurrozen3/24/2026Reiterated Rating$24.82$40.00Overweight$0.0000.00% ROIAPLSApellis Pharmaceuticals3/18/2026Lower Price Target$18.36$31.00Overweight$0.0000.00% ROICAMPCAMP4 Therapeutics3/6/2026Reiterated Rating$4.57Overweight$0.0000.00% ROIHROWHarrow3/4/2026Lower Price Target$38.60$91.00Overweight$0.0000.00% ROIBLTEBelite Bio3/3/2026Boost Price Target$172.27$266.00Overweight$0.0000.00% ROISRZNSurrozen2/19/2026Initiated Coverage$25.09$40.00Overweight$0.0000.00% ROISRZNSurrozen2/19/2026Initiated Coverage$26.93$40.00Overweight$0.0000.00% ROIWVEWAVE Life Sciences2/5/2026Boost Price Target$13.86$41.00Overweight$0.0000.00% ROIAPLSApellis Pharmaceuticals1/13/2026Lower Price Target$23.20$35.00Overweight$0.0000.00% ROICAMPCAMP4 Therapeutics12/11/2025Reiterated Rating$5.43Overweight$0.0000.00% ROIWVEWAVE Life Sciences12/9/2025Boost Price Target$18.52$34.00Overweight$0.0000.00% ROIBLTEBelite Bio11/24/2025Initiated Coverage$120.56$154.00Overweight$0.0000.00% ROIKRROKorro Bio11/13/2025Downgrade$31.42Neutral$0.0000.00% ROIHROWHarrow11/11/2025Reiterated Rating$38.74$94.00Overweight$0.0000.00% ROIXNCRXencor11/6/2025Boost Price Target$14.78$42.00Overweight$0.0000.00% ROIINVAInnoviva11/6/2025Boost Price Target$19.87$31.00Overweight$0.0000.00% ROIETNB89BIO10/31/2025Reiterated Rating$14.84Overweight$0.0000.00% ROIWVEWAVE Life Sciences10/27/2025Reiterated Rating$7.36$12.00Overweight$0.0000.00% ROITVRDTvardi Therapeutics10/13/2025Downgrade$6.21Neutral$0.0000.00% ROIXNCRXencor10/8/2025Upgrade$12.40Strong-Buy$0.0000.00% ROIXNCRXencor10/6/2025Reiterated Rating$12.07$40.00Overweight$0.0000.00% ROICAMPCAMP4 Therapeutics10/2/2025Set Price Target$2.98$7.00Overweight$0.0000.00% ROICAMPCAMP4 Therapeutics10/2/2025Upgrade$3.00$7.00Strong-Buy$0.0000.00% ROIAPLSApellis Pharmaceuticals8/1/2025Boost Price Target$23.27$40.00Overweight$0.0000.00% ROIAI Is Coming for Your Money (Ad)An AI model recently broke into a company on its own, with no instructions given. The incident raises a bigger question: what exactly do you own when your money is digital. Most of the American money supply is not paper cash, it is data on servers protected by a single password and network. See the three moves that could put part of your retirement out of reach from digital threats.See the three moves protecting retirement savings nowINVAInnoviva7/11/2025Initiated Coverage$19.06$26.00Overweight$00.0000.00% ROITVRDTvardi Therapeutics7/11/2025Initiated Coverage$22.67$52.00Overweight$0.0000.00% ROIHROWHarrow7/11/2025Initiated Coverage$31.37$76.00Overweight$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenBarclaysRoyal Bank Of CanadaMorgan StanleyJefferies Financial GroupThe Goldman Sachs GroupBMO Capital MarketsSanford C. BernsteinBerenberg BankBNP Paribas ExaneCompass PointPiper SandlerCanadian Imperial Bank of CommerceWeiss RatingsUBS Group Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
